116 results
8-K
EX-99.1
RVNC
Revance Therapeutics Inc
9 May 24
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
4:08pm
quarter ended March 31, 2024, compared to $50.9 million for the same period in 2023.
Research and development (R&D) expenses for the first quarter ended … of amortization)
Selling, general and administrative
Research and development
Amortization
Total operating expenses
Loss from continuing operations
Interest income
424B5
RVNC
Revance Therapeutics Inc
5 Mar 24
Prospectus supplement for primary offering
5:00pm
, as well as for working capital, research and development and general corporate purposes. See “Use of Proceeds” on page S-10 for additional information … manufacturing costs were incurred and expensed to research and development expense, and the employee retention credit;
S-6
our ability to successfully
424B5
RVNC
Revance Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
6:39am
into the therapeutics market, as well as for working capital, research and development and general corporate purposes. See “Use of Proceeds” on page S-10 … lines, for which the related manufacturing costs were incurred and expensed to research and development expense, and the employee retention credit;
S
8-K
EX-99.1
la46h67nj00
28 Feb 24
Provides Corporate Update
4:07pm
8-K
EX-10.1
y6r9k3qrfy4
13 Feb 24
Departure of Directors or Certain Officers
4:28pm
S-3ASR
e4umvo tp6lzsdsd
14 Nov 23
Automatic shelf registration
4:22pm
8-K
EX-99.1
vq3yylor
8 Nov 23
Provides Corporate Update
4:09pm
8-K
e0fyo9ogjaj9b7b5a
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-99.1
0kdsh514jh7y6f6s 0k
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-99.1
k1gjzvgzccyiu5
8 Aug 23
Provides Corporate Update
4:08pm
8-K
EX-99.1
85o2s81bd dn
9 May 23
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
4:07pm